Anzalone Christopher Richard bought ARWR
December 29, 2025 · Form 4 insider transaction
Anzalone Christopher Richard bought 35,181 shares of Arrowhead Pharmaceuticals, Inc. at $6.15 per share, a transaction worth $216.4K. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
35,181
Price
$6.15
Total value
$216.4K
InsiderAnzalone Christopher Richard
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateDecember 29, 2025
Filing dateDecember 30, 2025
Shares owned after3,841,107
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.